The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

CDDF JOINT MEETING: IBCD 2023

Innovations and Biomarkers in Cancer Drug Development Conference (IBCD 2022)

POSTPONED TO SPRING 2023, In-person Conference – Brussels (BE)

 

The Innovations and Biomarkers in Cancer Drug Development Conference (IBCD2023), co-organized by CDDF, EORTC, EMA, NCI and AACR, will take place in SPRING 2023 in Barcelona, Spain.

The IBCD 2023 edition tackles the difficult questions in drug and biomarker development, and will explore answers to the burning questions still out there.

  • To what extent is Whole Genome Sequencing a hype or does it have real value for health care settings?
  • Will Real-World data challenge classical trial designs?
  • Aren’t we fooled by biased biomarker-statistics in biomarker-driven trials?
  • Will Real-World data challenge classical trial designs?
  • Are Laboratory-Developed test a good alternative to regulatory-approved assays?

A panel of pathologists, clinical researchers, industry representatives, regulators and patient advocates will address critical issues in drug and biomarker development such as real word data challenges, Whole Genomic Sequencing, biomarker-driven trials and much more.

For any questions, please contact the IBCD 2022 secretariat: events@eortc.org 

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752

info@cddf.org
Tel: +32 2 880 62 70